Glenmark Specialty S.a.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals S.a.

Ulhas R Dhuppad

Chandrakant Dhatrak

Ashok Katkurwar

Rajesh Ankam

Yashwant Gupta

Sunil Chaudhari

Franciscus Koppenhagen

Suresh Rajurkar

Alkesh Kasliwal

Neelima Khairatkar-Joshi

Abhay Kulkarni

Vikram Mansingh Bhosale

Chad Oh

Patrick Keohane

Piyush Agarwal

Sudeesh K Tantry

Dinesh Pradeep Wale

Abraham Thomas

Rachel Striebig

Suresh Mahadev Kadam

Scott Alexander Lewis

Matthew Allen

Lai Chiu Tang

Julianne Berry

Michael Crick

A V V P S Raghuveer

Stuart Robert Abercrombie

Nitin Babulal Bhamre

Atul Chopade

Girish Ramakrishna Trivedi

Madhusudhan Bommagani

Akhilesh Dayanand Sharma

Rahul Kapse

Prashant Dongre

Vaijnath Aravat

Sushrut Kulkarni

Someshwar Navhat

Nilesh Jain

Nilesh Jayantilal Jain

Raveendra Pai

Rakshit Trivedi

Ramakant Chanagare

Ramprasad Murugan

Mahadeorao S Rase

Jitendra Patil

John William Sanford Hale

Ram Reddy Patlolla

Thomas Stephen Collings

Matthew David Allen

Rachel Victoria Striebig

The present invention relates to a metered dose inhaler device comprising a stable inhalable composition of ipratropium bromide, contained in a canister fitted with a metering valve, an actuator and a dose indicator. The present invention also relates to a process for preparing such a pharmaceutical composition and its use in the treatment of respiratory disorders such as for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema in a subject in need thereof (e.g., a human).

Metered dose inhaler for ipratropium bromide solution

A nasal dispensing device and pharmaceutical composition includes a container; a dispenser head having at least a pump, a dispensing channel, and a dispensing orifice; a dip tube; and a pharmaceutical composition comprising mometasone, an ester thereof (e.g., mometasone furoate), or a salt thereof and olopatadine or its salt (e.g., olopatadine hydrochloride). The container can have a conically shaped internal bottom, angled downwardly toward a center, and a further angularly deepened well, centrally located, with the dip tube extending into the well. An optional cap is provided that includes a sealing sleeve communicating in a seal tight manner with a perimeter of a lateral wall of the dispenser head.

Dispensing device and pharmaceutical composition for the treatment of rhinitis

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine

The present invention relates to a mupirocin topical pharmaceutical composition in a pump device, and its use for dispensing predetermined quantities of mupirocin for treating skin lesions.

Mupirocin cream in pump device

The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Tiotropium inhalation solution for nebulization

The present invention relates to a nanoparticulate formulation comprising a transient receptor potential ankyrin-1 receptor ('TRPA1') antagonist. Particularly, the present invention relates to a nanoparticulate formulation comprising a thienopyrimidinedione derivative as a TRPA1 antagonist and a surface stabilizer; a process for preparing such formulation; and its use in treating a respiratory disorder or pain in a subject.

Nanoparticulate formulation comprising a TRPA1 antagonist

The present disclosure relates to a nebulization composition comprising tiotropium and formoterol for the treatment of inflammatory or obstructive airway disease. The present disclosure also relates to a process for preparing the composition.

Nebulizable compositions of tiotropium and formoterol

The present invention relates to a dry powder inhaler for administering a medicament via oral inhalation route to a subject. Particularly, the dry powder inhaler according to present invention is suitable for delivering accurate doses of a medicament in different ranges of inspiratory capacity of the subject.

Dry powder inhaler

Growing community of inventors

Maharashtra, India

Ulhas R Dhuppad